Sign in
SESN Stock Price, Chart, Stats & News
Sesen Bio, Inc.
Save
127.96M
Market cap
–
Current P/E
–
Forward P/E
SESN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -1048.06% |
Pretax margin | -294.62% |
Net margin | -292.77% |
Effective tax rate | 0.63% |
ROA | 474.84% |
ROE | -111.70% |
D/E | -0.88x |
Interest coverage ratio | -173.80x |
SESN valuation
P/E | – |
P/S | -12.04x |
P/B | -30.31x |
P/CF | -0.35x |
P/FCF | -1.71x |
P/OCF | -0.35x |
PEG | 0.00x |
EV multiple | 2.66x |
About
Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials.
Similar securities
Based on sector and market capitalization
Report issue